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Background: Cancer invasion and metastasis develops through a series of steps that involve the loss of cell to cell
and cell to matrix adhesion, degradation of extracellular matrix and induction of angiogenesis. Different protease
systems (e.g., matrix metalloproteinases, MMPs) are involved in these steps. MMP-10, one of the lesser studied
MMPs, is limited to epithelial cells and can facilitate tumor cell invasion by targeting collagen, elastin and laminin.
Enhanced MMP-10 expression has been linked to poor clinical prognosis in some cancers, however, mechanisms
underlying a role for MMP-10 in tumorigenesis and progression remain largely unknown. Here, we report that
MMP-10 expression is positively correlated with the invasiveness of human cervical and bladder cancers.
Methods: Using commercial tissue microarray (TMA) of cervical and bladder tissues, MMP-10 immunohistochemical
staining was performed. Furthermore using a panel of human cells (HeLa and UROtsa), in vitro and in vivo experiments
were performed in which MMP-10 was overexpressed or silenced and we noted phenotypic and genotypic changes.
Results: Experimentally, we showed that MMP-10 can regulate tumor cell migration and invasion, and endothelial cell
tube formation, and that MMP-10 effects are associated with a resistance to apoptosis. Further investigation revealed
that increasing MMP-10 expression stimulates the expression of HIF-1α and MMP-2 (pro-angiogenic factors) and PAI-1
and CXCR2 (pro-metastatic factors), and accordingly, targeting MMP-10 with siRNA in vivo resulted in diminution of
xenograft tumor growth with a concomitant reduction of angiogenesis and a stimulation of apoptosis.
Conclusion: Taken together, our findings show that MMP-10 can play a significant role in tumor growth and
progression, and that MMP-10 perturbation may represent a rational strategy for cancer treatment.
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The extracellular microenvironment is an integral and
dynamic scaffold that dictates cell function and cell fate
for both normal and cancer cells. Cancer invasion and
metastasis develop through a series of steps that involve
the loss of cell to cell and cell to matrix adhesion, deg-
radation of extracellular matrix and induction of angio-
genesis. A number of protease systems, including the
matrix metalloproteinases (MMPs) are involved in these
steps. MMPs are essential regulators of the tissue micro-
environment through their ability to control extracellular* Correspondence: crosser@cc.hawaii.edu
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unless otherwise stated.matrix (ECM) turnover [1]. The MMP family is com-
prised of at least 24 members that can collectively
process virtually any component of the ECM [2], thereby
influencing basic cellular processes that underlie cancer
development, e.g., cell dissociation, cell death and cell
division.
Based on our previous biomarker studies, we were in-
terested in studying MMP-10, a relatively understudied
MMP in cancer biology. MMP-10 (also known as stro-
melysin 2) is generally limited to epithelial cells [3] and
can target pro-MMP-1, -7, -8, -9, -13, collagen type III,
IV, V, gelatin, elastin, fibronectin, proteoglycans and lam-
inin [4], activities that have been shown to promote
tumor cell invasion [5]. It has been demonstrated that
MMP-10 expression is increased in several human tumorsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cancer [8], esophageal cancer [9], skin cancer [10] and
non-small cell lung cancer (NSCLC) [11]. These findings
suggest that MMP-10 may play an important role in the
development and progression of malignant tumors.
In this study, we monitored MMP-10 expression in co-
horts of human tumor tissues, and investigated the
mechanistic role of this MMP using a panel of in vitro
and in vivo studies. We found that MMP-10 expression
is positively correlated with an invasive phenotype in
both human cervical and bladder cancers. Experimen-
tally, we found that MMP-10 expression is tightly
controlled and can be mediated by three-dimensional
culture. We show that MMP-10 regulates migration/
invasion capability, endothelial cell tube formation, and
induces the expression of key angiogenic and metastatic
factors (e.g., MMP-9; hypoxia inducible factor-1 alpha,
HIF-1α; chemokine (C-X-C motif ) receptor 2, CXCR2;
and plasminogen activator inhibitor-1, PAI-1). Further-
more, MMP-10 activity causes resistance to apoptosis
via both the intrinsic and extrinsic apoptotic pathways.
Lastly, we demonstrate that targeting MMP-10 in a hu-
man cervical cancer xenograft model with siRNA inhib-
ited angiogenesis and induced apoptosis, resulting in a
significant reduction in the growth of xenograft tumors.
These results suggest that MMP-10 has distinct, multiple
roles in tumor cell-matrix interactions that favor tumor
progression.
Methods
Immunohistochemcal (IHC) staining of tissue microarrays
With IRB approval from MD Anderson Cancer Center
Orlando, commercial tissue microarrays (TMA) (CR805
and BL2082, BL1002, US Biomax, Inc., Rockville, MD)
constructed from clinical samples obtained from a cohort
of 80 patients (70 cervical cancers; 67 adenocarcinoma
and 3 squamous cell carcinoma and 10 benign cervical
tissues) and from a cohort of 258 patients (188 bladder
cancers and 70 benign bladder tissues) were examined
by immunohistochemical staining. Clinical staging was
recorded for cervical cancer using International Feder-
ation of Gynecology and Obstetrics (Stages 0-IV) and for
bladder cancer using TNM staging (Stage I-IV). Protocol
and antibody details are available in Additional file 1.
Cells and reagents
Human cervical cancer cell line HeLa (adenocarcinoma
from ATCC, Manassas, VA) and benign human bladder
cell line, UROtsa (a generous gift from Dr. Donald Sens
at the University of North Dakota School of Medicine,
Grand Forks, ND) were available for analysis. HeLa cells
were maintained in RPMI 1640 media and UROtsa cells
were maintained in DMEM media as previously de-
scribed [12]. Primary human umbilical vein endothelialcell (HUVEC, Cambrex) was cultured in EBM-2 basal
media supplemented with EGM-2 MV Kit (Lonza) con-
taining 2% FBS. HUVEC cells of passage 6 to 8 were
used. To ensure optimal siRNA delivery in xenograft tu-
mors, in vivo-jetPEI (Polyplus-transfection Inc. NYC, NY),
a linear polyethylenimine, was used in conjunction with
siRNA [13].
Gene transfection for stable cell lines
A plasmid with a sequence verified human MMP-10
cDNA cloned within pCMV6-Entry vector and plasmid
with vector alone (Origene Technologies) were trans-
fected into HeLa cells using Fugene HD transfection re-
agent (Roche Diagnostics) to create HeLa-MMP-10OE
and HeLaEmpty, respectively. Stable transfectants were se-
lected with 1,200 μg/ml of G418 (Life Technologies,
Inc.) for 14 days and subcloned by limiting dilution in
96-well plates. Integration of the transfected gene into
chromosome was confirmed by reverse transcriptase-
PCR (data not shown). Stable cell lines were maintained
in media containing 500 μg/ml of G418 for HeLa clones
(HeLa-MMP-10OE and HeLaEmpty).
Transfection of small interfering RNA (siRNA)
UROtsa cells were transfected for 6 hrs with synthesized
MMP-10 siRNA (UROtsa-MMP-10KD-1 and UROtsa-
MMP-10KD-2) or negative control siRNA (UROtsa-MMP-
10Scr) (Life Technologies) using 6 well plates with a
100-pmol of siRNA and 5 μl of lipofectamine 2000
(Life Technology). Forty-eight hrs after transfection, trans-
fected cells were replated for further experiments. MMP-
10 siRNA sequences are listed in Additional file 1.
Immunoblotting
Cell lysate and immunoblotting were performed using
standard protocols as previously described [14]. Anti-
body details are available in Additional file 1.
Quantitative reverse transcriptase-PCR
RNA was extracted from cells using RNeasy mini kit
(Qiagen) as per manufacturer’s instructions. Conversion to
cDNA was achieved through High Capacity cDNA Reverse
Transcription kit (Life Technologies). Quantitative reverse
transcriptase (RT)-PCR was carried out using ABI 7300
Real-Time PCR System (Life Technologies) in a 20 μl reac-
tion volume containing 1 μl of the first-strand cDNA, 1 μM
of gene-specific TaqMan primer and probe mix. Primer sets
can be found in Additional file 1. Relative fold changes
in mRNA levels were calculated after normalization to
GAPDH using the comparative Ct method [15].
Zymography
Thirty micrograms of total cell lysate from the parental
cervical cancer cell line HeLa and parental urothelial cell
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following clones: HeLa-MMP-10OE, HeLaEmpty, UROtsa-
MMP-10KD1&2 and UROtsa-MMP-10Scr, were electro-
phoresed on 10% SDS-polyacrylamide gels containing
1 mg/ml casein (Sigma, St. Louis, MO) under non-
reducing conditions. After electrophoresis and SDS re-
moval, MMP-10 renaturation was achieved by washing
the gel for 1 hr in buffer containing 2.5% Triton-X 100,
50 mM tris pH 7.4, 5 mM CaCl2, and 1 μM ZnCl2.
Gels were then incubated in a reaction buffer contain-
ing 50 mM Tris pH 7.4, 5 mM CaCl2, 1 μM ZnCl2
and 0.02% NaN3 pH 8.0 for 18 hrs at 37°C, followed
by staining with Coomassie blue. MMP-10 activity
was indicated by the degradation of casein. Gels were
photographed using the KODAK Gel Logic 200 Im-
aging System with Carestream Molecular Imaging Soft-
ware Standard Edition v5.0.7.24 (Carestream Health,
Rochester, NY).
Cell migration and invasion assays
Migration assays were performed in 6 well two-tier
invasion chambers (Collaborative Biomedical Products,
Bedford, MA, USA), using a protocol similar to that
used successfully by our group [15]. Polycarbonate
membranes were coated with 4 mg/ml growth factor
reduced Matrigel (BD Biosciences, San Jose, CA) as de-
scribed for invasion assays, control inserts (migration
only) contained no coating. Two separate experimental
designs were tested. First, HeLa-MMP-10OE, HeLaEmpty
and UROtsa-MMP-10KD1&2, UROtsa-MMP-10Scr cells
were added to each insert at a density of 105 cells/ml/well
in RPMI media. The lower chamber contained RPMI
media with 10% FBS as chemoattractant. After incuba-
tion in a humidified incubator in 5% CO2 at 37°C for
24 hrs, the cells on the top of the polycarbonate mem-
brane were removed. The cells attached to the bottom
of the membrane stained for 1 hr with cell viability in-
dicator Calcein AM Fluorscent Dye (BD Biosciences,
Franklin Lakes, NJ) and quantified using the FLUOstar
OPTIMA at 495 mm excitation and 515 nm emission
(BMG LABTECH Inc., Cary, NC).
In additional, HUVEC cells were added to each insert
at a density of 105 cells/ml/well in RPMI media. The
lower chamber contained conditioned media from HeLa-
MMP-10OE, HeLaEmpty, UROtsa-MMP-10KD1&2 and
UROtsa-MMP-10Scr. After 24 hrs, the HUVEC cells on
the top of the polycarbonate membrane were removed,
while the HUVEC cells attached to the bottom of the
membrane were stained for 1 hr with cell viability indica-
tor Calcein AM Fluorscent Dye and quantified using the
FLUOstar OPTIMA. For the migration and invasion as-
says, at least three independent experiments consisting of
each condition tested in triplicate wells was used to cal-
culate mean ± SD values.Endothelial cell tube formation assays
Matrigel (BD Biosciences) was added to 96 well plates
(40 μl per well) and allowed to solidify for 30 min at
37°C as previously described [16]. HUVEC cells were
seeded on top of Matrigel in triplicates at a density
of 104 cells per well in conditioned media from cultured
HeLa-MMP-10OE, HeLaEmpty, UROtsa-MMP-10KD1&2
and UROtsa-MMP-10Scr and allowed to incubate for
6 hrs. Next, images of capillary tube formation were
captured using Leica DMIL inverted microscope. The
angiogenic activities were quantitatively evaluated by
measuring the total tube length of capillary tube in at least
four viewed fields per well. At least three independent ex-
periments consisting of each condition tested in triplicate
wells was used to calculate mean ± SD values.
RT2 Profiler PCR arrays for angiogenesis and metastasis
Cellular RNA from HeLaEmpty and HeLa-MMP-10OE
was recovered and converted to cDNA as described
above. RT2 Profiler ‘human angiogenesis’ PCR arrays,
(Catalog # PAHS-024ZA; SABiosciences) and RT2 Profiler
‘human metastasis’ PCR arrays, (Catalog # PAHS-028ZA;
SABiosciences) were analyzed in duplicate according
to the manufacturer's instructions (www.sabiosciences.
com/pcrarraydataanalysis.php) by quantitative reverse
transcriptase (RT)-PCR carried out using ABI 7300 Real-
Time PCR system (Life Technologies). The specificity of
the SYBR Green assay was confirmed by melting curve
analysis. Relative fold changes in mRNA levels were calcu-
lated after normalization to housekeeping control gene
targets using the comparative Ct method.
Caspase activity assay
HeLa-MMP-10OE and HeLaEmpty cells were lysed in cas-
pase assay buffer containing 50 mM HEPES (pH 7.5),
100 mM NaCl, 2 mM EDTA, 0.1% CHAPS, 10% sucrose
and 5 mM DTT. Aliquots of 6 mg of crude cell lysate
were incubated with caspase-3 substrate Ac-DEVD-
AMC (Pharmingen, San Diego, CA) at 37°C for 30 min.
The caspase-3 activity was quantified in a FLUOstar Op-
tima Reader (BMG LABTECH, Ortenberg, Germany)
with excitation at 380 nm and emission at 440 nm. At
least three independent experiments consisting of each
condition tested in triplicate wells was used to calculate
mean ± SD values.
Annexin V apoptosis assay
HeLa-MMP-10OE and HeLaEmpty cells were assessed in a
LIVE/DEAD Annexin V apoptotic assay (BD Biosci-
ences, Franklin Lakes, NJ) by flow cytometry. Further-
more, resistance to apoptosis was also determined in
these same cells by exposing the cells to 1 μM of staur-
osporine (an agent capable of inducing apoptosis) for
5 hrs. In brief, after 5 hrs of exposure to staurosporine,
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with propidium iodide (PI) in tandem with an APC-
conjugated annexinV antibody according to the manufac-
turer’s instructions (BD Biosciences, San Jose, CA) and
quantitated via flow cytometry using the BD FACScaliber
with Cell Quest Pro Software (BD Biosciences, San Jose,
California) and FlowJo (TreeStar Inc., Ashland, OR). Vi-
able cells were negative for both annexin V and PI, early
apoptotic cells exhibit externalization of phosphati-
dylserine and were annexin V positive but have an intact
plasma membrane and were PI negative, while dead and
damaged cells which have subsequently lost their mem-
brane integrity were positive for both annexin V and PI.
Mitochondrial membrane potential analysis
Analysis of mitochondrial membrane potential was per-
formed as previously reported by our group [14]. Briefly,
for the analysis of mitochondrial membrane potential
(DCm), HeLa-MMP-10OE and HeLaEmpty cells were seeded
at 5 x 105 cells in 10 cm tissue culture dishes for 24 hrs.
Cells were then treated with 1 μM of staurosporine for 0,
1, 5 and 18 hrs. Next, cells were trypsinized, washed
with 1 x PBS, incubated with medium containing JC-
1 dye (10 μg/ml) for 20 min at 37°C. Lastly, the cells were
washed and resuspended in 1 ml PBS for fluorescent flow
cytometry analysis using FACScan flow cytometer (Becton
Dickinson) measuring at least 104 gated cells. Mitochon-
drial depolarization is indicated by a decrease in orange/
green fluorescence ratio. All mitochondrial membrane po-
tential analyses were performed in triplicate.
Xenograft tumorgenicity
Animal care was in compliance with the recommenda-
tions of The Guide for Care and Use of Laboratory
Animals (National Research Council) and approved by
our local IACUC at the University of Central Florida
and MD Anderson Cancer Center Orlando. First, the
subcutaneous tumorigenicity assay was performed in
athymic BALB/c (nu/nu) mice, 6 to 8 wks old purchased
from Harlan Laboratories (Indianapolis, IN) by inoculat-
ing 106 HeLa cells as described previously [17,18]. After
two weeks, mice were divided randomly into four treat-
ment groups (control, human siRNA MMP-10; 10 μg of
siRNA with 1.2 μl of in vivo-jetPEI at a N/P ratio of 6
according to the manufacturer’s protocol, mouse siRNA
MMP-10; 10 μg of siRNAs with 1.2 μl of in vivo-jetPEI
at a N/P ratio of 6 and combination of human and
mouse siRNA MMP-10; 5 μg of human siRNA and 5 μg
of mouse siRNA with 1.2 μl of in vivo-jetPEI N/P ratio
of 6) and treatment was initiated. siRNA therapy was ad-
ministered intratumorally twice weekly for five weeks.
Control mice received 10 μg of non-target siRNA mixed
with 1.2 μl of in vivo-jetPEI N/P ratio of 6 on the same
schedule. At least 10 animals were in each group. At thetermination of the experiment, mice were sacrificed and
tumors resected for IHC analysis.
Immunohistochemical (IHC) analysis of xenograft tumors
Immunohistochemistry was conducted as described in
refs. 17 and 18. Microvessel density (MVD) index was
calculated as previously described [19]. Details and anti-
bodies listed in Additional file 1.
Statistical analyses
All data are expressed as mean ± standard deviation (SD).
Statistical analyses were conducted using GraphPad Prism
5.0 (GraphPad Software, Inc.). For most comparisons,
a 2-tailed unpaired Student t test or Mann-Whitney
U test was conducted. The comparison between MMP-10
expression in low-grade, high-grade, low stage and high
stage cancer was calculated using Fisher’s exact test. Differ-
ences were considered statistically significant at p < 0.05.
Results
MMP-10 expression is upregulated in cancer tissues
We monitored MMP-10 protein expression in a panel of
human cervical cancer tissues by immunohistochemical
staining of a commercial TMA comprised of 10 benign
specimens and 70 cancer tissues. Samples were semi-
quantitatively assessed by scoring the intensity of the
staining and the proportion of MMP-10-positive cancer
cells. Figure 1 shows representative negative images of
benign samples (Figure 1A), and weakly (1+, Figure 1B)
and strongly (3+, Figure 1C) positive staining in cervical
tumor samples. We observed that MMP-10 was prefer-
entially located in the epithelial component with scant,
scattered staining in the stroma, as seen in individual bi-
opsy cores (Figure 1D). Figure 1E provides a higher mag-
nification of the stromal component, while Figure 1F
illustrates the epithelial component. Analyses revealed
low immunoreactivity for MMP-10 in the epithelial com-
ponent of 50% of benign cervical tissue, and an absence of
high immunoreactivity (0%) in benign cervical tissue. Con-
versely, low immunoreactivity for MMP-10 was present in
the epithelial component of 8% of cancerous samples, and
high immunoreactivity was present in 54% of cancerous
samples, illustrating an increase in MMP-10 expression in
cancerous tissues (Figure 1G, p = 0.0002). Notably, inva-
sive cervical tumors showed significantly higher MMP-
10 immunoreactivity compared to non-invasive tumors
(Figure 1H, p = 0. 0012).
We have previously reported a significant increase in
the expression of MMP-10 transcripts in shed urothelia
from patients bearing bladder tumors relative to healthy
controls [20], and we subsequently confirmed that in-
creased soluble MMP-10 protein levels were indicative
of bladder cancer in two large, independent studies [21,22].
In this study, we evaluated MMP-10 expression through
Figure 1 MMP-10 expression is high in cervical cancer tissue. Representative images of benign cervical tissue (A), cervical tumor with weak
(B), and cervical tumor with strong (C) MMP-10 expression (brown). Representative image of a cervical tumor core on a tissue microarray
(D), MMP-10 expression in the tumor-associated stroma (E), and in the tumor epithelia (F). Scale bars, 100 μm. G, quantification of MMP-10
expression levels in benign cervical tissue (n = 10) vs. cervical tumor (n = 70). Increased MMP-10 expression was noted in cervical tumors
compared to benign cervical tissue. H, quantification of MMP-10 expression levels in low stage cervical tumors vs. high stage cervical tumors.
Increased MMP-10 expression was noted in high stage cervical tumors.
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cancer TMA (70 benign samples and 188 cancer samples).
Similar staining patterns to those found in the cervical can-
cers were noted in human bladder cancers (Additional
file 2: Figure S1A-I). Specifically, 41 of the 71 samples
from muscle invasive bladder cancer (MIBC) had mod-
erate or high expression for MMP-10, whereas 30 sam-
ples had low or no expression. From the 68 non-muscle
invasive bladder cancer (NMIBC) samples, 24 had mod-
erate or high expression and 44 had low or no expres-
sion (p < 0.01 - Additional file 2: Figure S1I), indicating
that MMP-10 expression increased in MIBC compared
to NMIBC.MMP-10 expression stimulates migration, and invasion
We next investigated whether MMP-10 might contribute
to key tumor cell processes including migration and inva-
sion. Though other MMPs (e.g., MMP-1, -2, -8, -9, -13)
have been linked to degradation of laminin, vitronectin,
fibronectin, enactin, collagen I-IV, MMP-10 has been
identified as a stromelysin which can degrade various
proteoglycan components of the ECM [23], thus facili-
tating tumor cell dissociation. Here, we utilized two
human cell lines for experimental perturbation of MMP-
10; the benign SV40 transformed urothelial line UROtsa
and the cervical cancer cell line HeLa (Figure 2A). MMP-
10 protein activity was demonstrated by zymography as
Figure 2 MMP-10 expression in HeLa and UROtsa human cell lines. A, MMP-10 expression was assessed by quantitative reverse transcriptase-PCR
(qPCR), and immunoblot (IB) analyses in HeLa and UROtsa cells. MMP-10 activity was assessed by zymography, demonstrated by the degradation
of casein. B, MMP-10 expression and activity was assessed by qPCR, immunoblot analyses and zymogram in stable HeLa clones; HeLa-MMP-10OE
overexpressing a functionally human MMP-10 in a pCMV6-Entry vector, and HeLaEmpty an empty-vector transfected control. C, MMP-10 assessed
by qPCR, immunoblot and zymography in UROtsa clones; UROtsa-MMP-10KD-1, UROtsa-MMP-10KD-2 functional knockdown clones transfected with
MMP-10 siRNA, and UROtsa-MMP-10Scr transfected with a scrambled siRNA control.
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Next, stable clones of HeLa cells that over-expressed
MMP-10 (HeLa-MMP-10OE) and its corresponding
control HeLaEmpty were created using plasmid DNA
transfection (Figure 2B). Thus, we did not knockdown
MMP-10 expression in human cervical cells. Stable
clones of UROtsa cells with reduced MMP-10 expres-
sion (UROtsa-MMP-10KD-1, UROtsa-MMP-10KD-2) plus
control line UROtsa-MMP-10Scr were established using
siRNA transfection (Figure 2C). Thus we did not overex-
press MMP-10 in human bladder cells. MMP-10 expres-
sion in these cells was confirmed at both mRNA and
protein levels, and activity was monitored by zymography.
While the HeLa-MMP-10OE clone had enhanced MMP-
10 expression and activity, MMP-10 expression andactivity were abrogated in both UROtsa-MMP-10KD-1 and
UROtsa-MMP-10KD-2 cells relative to control UROtsa-
MMP-10Scr cells (Figure 2B & C).
In an in vitromigration and invasion assay, the migratory
potential of HeLa-MMP-10OE was significantly enhanced
compared to HeLaEmpty (p = 0.012, Figure 3A). Similarly,
the migratory potential of UROtsa-MMP-10KD-1 and
UROtsa-MMP-10KD-2 cells was significantly reduced com-
pared to UROtsa-MMP-10Scr (p < 0.05, Figure 3B). The
same phenomena were observed in the invasion assay,
HeLa-MMP-10OE cells having significant enhance-
ment of invasion compared to HeLaEmpty cells (p = 0.002,
Figure 3A). No significant difference in invasive potential
was noted in UROtsa-MMP-10KD-1 and UROtsa-MMP-
10KD-2 compared to UROtsa-MMP-10Scr (Figure 3B).
Figure 3 MMP-10 promotes cellular migration and invasion. A, HeLa cells (parental, HeLaEmpty and HeLa-MMP-10OE) and B, UROtsa cells
(parental, UROtsa-MMP-10KD-1, UROtsa-MMP-10KD-2 and UROtsa-MMP-10Scr) were subjected to in vitro migration and invasion assays. Data are
average values and SDs of three independent experiments conducted in triplicate. Overexpression of MMP-10 in HeLa-MMP-10OE cells was noted
to correspond with an increase in migratory and invasive potential, while silencing of MMP-10 in UROtsa-MMP-10KD-1 resulted in a reduced
migratory potential. C, HUVEC cells were placed in the invasion chamber and then exposed to conditioned media in the lower chamber
from HeLa cells (parental, HeLa-MMP-10OE and HeLaEmpty), and UROtsa cells (UROtsa-MMP-10KD-1, UROtsa-MMP-10KD-2 and UROtsa-MMP-10Scr)
for in vitro migration and invasion assays. Data are average values and SDs of three independent experiments conducted in triplicate. Conditioned
media from HeLa-MMP-10OE cells that overexpressed MMP-10 was noted to induce migration and invasion of HUVEC cells. D, Capillary tube
formation of HUVECs cultured in conditioned media from HeLa-MMP-10OE and HeLaEmpty cells were quantified as total tube length per field
in micrometers and was noted to be enhanced when MMP-10 was overexpressed. Data are average values and SDs of three independent
experiments conducted in triplicate. E, Capillary tube formation in HUVECs cultured in conditioned media from UROtsa-MMP-10KD-1,
UROtsa-MMP-10KD-2 and UROtsa-MMP-10Scr cells were quantified as total tube length per field in micrometers and was noted to be inhibited
when MMP-10 was silenced. Data are average values and SDs of three independent experiments conducted in triplicate. *, p < 0.05.
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We also evaluated the ability of MMP-10 to influence
the migration and invasion of human endothelial cells.
HUVEC cells were tested for movement towards con-
ditioned media from parental HeLa, HeLaEmpty, and
HeLa-MMP-10OE cells in the assay described above.
For HUVEC cells, the conditioned media associated
with HeLa-MMP-10OE caused an increase in migration
(p = 0.013) and invasion (p = 0.002) compared to condi-
tioned media from HeLaEmpty cells (Figure 3C). No sig-
nificant difference in migratory or invasive potential was
noted in HUVEC cells exposed to conditioned media
from UROtsa-MMP-10KD-1 and UROtsa-MMP-10KD-2
compared to UROtsa-MMP-10Scr or parental UROtsa
cells (data not shown).
As a surrogate for potential effects on angiogenesis,
we set out to investigate whether MMP-10 expressionmight influence endothelial tube formation. Conditioned
media from the test cell lines was utilized in an in vitro
tube formation assay. The total length of tube-like struc-
tures formed by HUVECs on growth factor-reduced
Matrigel was significantly enhanced by treatment with
conditioned media from HeLa-MMP-10OE cells com-
pared to HeLaEmpty cells (~220%, Figure 3D). Conversely,
the total length of tube-like structures was significantly
reduced when HUVECs were treated with conditioned
media from UROtsa-MMP-10KD-1 and UROtsa-MMP-
10KD-2 (~72% and ~68%, respectively; Figure 3E) com-
pared to UROtsa-MMP-10Scr.
To follow up on these observed effects we profiled the
expression of key angiogenic and metastatic factors in
the manipulated cell lines using commercial PCR arrays.
Significant differential expression was observed for many
gene transcripts in HeLa-MMP-10OE cells relative to the
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genes implicated in angiogenesis (Figure 4A and Additional
file 3: Table S1), differential expression of HIF-1α
and MMP-9 was confirmed by Western blot analysis
(Figure 4B). Among a panel of genes identified from the
metastasis PCR array (Figure 4C and Additional file 4:
Table S2), differential expression of CXCR2 and PAI-1 was
confirmed by Western blot (Figure 4D). Thus, the expres-
sion of MMP-10 was associated with the upregulation of
key angiogenic and metastatic proteins in HeLa cells, fac-
tors which could facilitate tumor growth and progression.
MMP-10 influences apoptosis
Previous investigators have reported a link between
MMP-9 and MMP-10 and an ability to induce p53-
mediated apoptosis [24]. Here, we set out to determine
if MMP-10 could regulate apoptosis within HeLa cells
that have wild-type p53. Using a caspase activity assay,
we investigated whether overexpression of MMP-10 in
HeLa cells resulted in a reduction in apoptosis in the
presence and absence of the apoptosis-inducing agent,Figure 4 MMP-10 regulates the expression of key angiogenic and me
quantitative RT-PCR assessed the expression of 84 gene transcripts. Ge
housekeeping genes (β-actin, B2M, GAPDH, HPRT and RPLP). Changes in
changes listed in Additional file 3: Table S1) were noted in HeLa-MMP-10
the differential expression of HIF-1α and MMP-9 at the protein level. GAP
evaluated by quantitative RT-PCR assessed 84 gene transcripts. Gene expres
genes (β-actin, B2M, GAPDH, HPRT and RPLP). Changes in expression of Src,
HeLa-MMP-10OE cells relative to HeLaEmpty cells. D, Western blot analysis con
served as a loading control.staurosporine (1 μM) (Additional file 5: Figure S2).
HeLa-MMP-10OE cells were noted to have a 21% reduc-
tion in caspase activity over HeLaEmpty cells (p = 0.025,
Figure 5A). Similarly in an Annexin V apoptosis assay,
the percentage of cell undergoing apoptosis was re-
duced by 28% in HeLa-MMP-10OE cells compared to
HeLaEmpty cells (p = 0.029) (Figure 5B). Analysis of mito-
chondrial membrane potential (DCm) revealed a signifi-
cantly higher DCm, as noted by the increase in FL2/
FL1 fluorescence ratio, in HeLa-MMP-10OE relative
to HeLaEmpty cells (Figure 5C). HeLa-MMP-10OE cells
proved to possess a higher DCm at all time points post-
staurosporine treatment, confirming a role for MMP-10
in resistance to staurosporine-induced apoptosis. Fur-
thermore, we assessed the expression of a panel of apop-
totic factors implicated in either the intrinsic or extrinsic
apoptosis pathways (Figure 5D). Western blot data re-
vealed that when MMP-10 was overexpressed, members
of the intrinsic pathway; Bax and Bak were reduced,
while Bcl-xl was increased. Monitoring members of
the extrinsic apoptosis pathway revealed that MMP-10tastatic factors. A, Angiogenesis RT2 Profiler PCR Arrays evaluated by
ne expression levels were normalized to the combination of five
expression of HIF-1α, MMP-9, MMP-2, IGF-1 transcripts (see other
OE cells relative to HeLaEmpty cells. B, Western blot analysis confirmed
DH served as a loading control. C, Metastasis RT2 Profiler PCR Arrays
sion levels were normalized to the combination of five housekeeping
MMP-2, PAI-1, CXCR2 (also see Additional file 4: Table S2) were noted in
firmed differential protein expression of PAI-1 and CXCR2. GAPDH
Figure 5 Overexpression of MMP-10 results in inhibition of apoptosis. A, Caspase activity assay was performed with HeLa-MMP-10OE and
HeLaEmpty cells after exposing the cells to the apoptotic-inducing agent, staurosporine at 1 μM. At least three independent experiments
performed in triplicate were used to calculate mean ± SD values. *, p < 0.05. The apoptotic effects of staurosporine were abrogated by MMP-10
overexpression. B, Annexin V apoptotic assays were also performed with HeLa-MMP-10OE and HeLaEmpty cells as described above. Assays confirmed
that high expression of MMP-10 was associated with resistance to induced apoptosis. C, Changes in mitochondrial membrane potential (DCm) in
HeLa-MMP-10OE and control HeLaEmpty cells were assessed by flow cytometric analysis. At least three independent experiments performed in
triplicate wells were used to calculate mean ± SD values. *, p < 0.05. High expression of MMP-10 was associated with a significant increase in
DCm compared to control. D, Western blot analysis was performed on the above cell lines confirming MMP-10 overexpression was associated
with the expression of apoptosis factors. For example, the expression of key intrinsic apoptotic pathway factors (Bcl-xl, Bax and Bak), and factors in
the extrinsic apoptotic pathway (FasL and cleaved caspase-8) were altered when MMP-10 was overexpressed. GAPDH served as controls.
E, The expression of the proteins from the Western blot from panel D was quantitated and plotted to illustrate relative expression of the apoptotic
associated proteins.
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and cleaved caspase-8. Thus, this is the first report dem-
onstrating MMP-10 activity confers HeLa cell resistance
to apoptosis through multiple factors related to the in-
trinsic and extrinsic apoptosis pathway.
MMP-10 siRNA therapy inhibits xenograft tumor growth
HeLa cells form robust subcutaneous xenografts in athy-
mic mice. Following our in vitro findings, we hypoth-
esized that perturbation of MMP-10 in vivo could
influence the tumorigenicity of HeLa cell xenografts.
Though parental HeLa cells were found to express very
low levels of MMP-10 in monolayer cultures, in prelim-
inary xenograft tests, we noticed that MMP-10 levels sig-
nificantly increased as three-dimensional HeLa xenografttumors were established. Moreover, MMP-10 from both
human and mouse sources were evident in xenograft tis-
sue, with mouse MMP-10 expression being at a high level
(Figure 6A). Thus, when we set out to inhibit MMP-10 in
the xenograft experiments, we targeted both human and
mouse MMP-10 using distinct siRNA reagents.
Mice in each test group were injected intratumorally
twice weekly with appropriate siRNA. At the end of the
5-week study, untreated HeLa xenografts, and xeno-
grafts treated with a scrambled mouse and human con-
trol siRNA reagent mix, reached an average volume of
833 mm3 and 882 mm3, respectively (Figure 6B). HeLa
xenografts treated with human MMP-10 siRNA reached
an average volume of 629 mm3 (29% reduction com-
pared to control siRNA, p < 0.001), while HeLa xenografts
Figure 6 MMP-10 regulates HeLa xenograft tumorigenicity. A, Human and mouse MMP-10 expression in subcutaneous HeLa tumors and in
parental HeLa cells grown in culture was assessed by qPCR. Gene expression level was normalized to GAPDH. Cultured parental HeLa cells
expressed minimal MMP-10, but when grown in a subcutaneous mouse model, increases in both human and mouse MMP-10 were noted.
B, Tumor growth was established by subcutaneous injection of parental HeLa cells into athymic nude mice (nu/nu). PBS (negative control),
scrambled siRNA (negative control), human MMP-10 siRNA and murine MMP-10 siRNA reagents were injected intratumorally twice weekly as
described in Materials and Methods. Tumor size was plotted as mean ± SD from the four treatment groups (n = 10/group). Treatment with
siRNA MMP-10 human alone, siRNA MMP-10 mouse alone and the combination of human and mouse siRNA MMP-10 were associated with
a significant reduction in tumor burden. *, p < 0.05. C, Human MMP-10 and mouse MMP-10 expression in excised tumors are shown (images
400 ×, Bar = 50 μm). A reduction in MMP-10 and CD31 expression along with an induction of cleaved caspase-3 was noted in tumors treated with
human MMP-10 siRNA alone, mouse MMP-10 siRNA alone and the combination of human and mouse siRNAs. D, MMP-10 expression was quantified
based on MMP-10 staining. E, Microvessel density (MVD) was quantified based on CD31 staining. Apoptotic index (AI) was quantified based on cleaved
caspase-3 staining. Data are presented as mean ± SD, *, p < 0.05 compared to negative control.
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545 mm3 volume (38% reduction compared to control
siRNA, p < 0.001). HeLa xenografts treated with a com-
bined human and mouse MMP-10 siRNA mix established
tumors of only 474 mm3, a 46% reduction compared to
control (p < 0.001), however, this was not significantly dif-
ferent from either human siRNA MMP-10 or mouse
siRNA MMP-10 treatment alone (Figure 6B). A clear re-
duction in MMP-10 expression was identified in xenograft
tumors treated with either human or mouse siRNA MMP-
10 (Figure 6C & D). Interestingly, when tumors were
treated with either human or mouse MMP-10 siRNA
alone, a reduction in the expression of the other species
MMP-10 was also noted (Figure 6D). Cross reactivity be-
tween the species-specific siRNAs was not noted in vitro
(data not shown), thus, we speculate that there is some
positive feedback link between mouse stromal MMP-10
and HeLa tumor cell MMP-10 production.
Expression levels of the vasculature marker CD31
were monitored in xenograft sections to establish a
microvessel density (MVD) index. Analyses revealed a
severe reduction of CD31 positivity in HeLa xenograft
tumors treated with either human or mouse MMP-10
siRNA. MVD calculated in xenografts treated with the hu-
man MMP-10 siRNA, the mouse MMP-10 siRNA, and
the combination of human and mouse MMP-10 siRNA
groups, revealed a reduction of 50%, 66% and 73%, respect-
ively, relative to control siRNA treatment (Figure 6E).
Lastly, the expression level of caspase-3 was evalu-
ated to estimate an apoptotic index (AI). AI of xenografts
treated with the human MMP-10 siRNA, the mouse
MMP-10 siRNA, and the combination of human and
mouse MMP-10 siRNA confirmed an increase of 38%, 45%
and 87%, respectively, compared to control siRNA treat-
ment (Figure 6E). However, the combination of human
and mouse MMP-10 siRNA did not result in significantly
altered MVD or AI relative to those treated with human or
mouse MMP-10 siRNA alone. The in vivo observations
corroborate the in vitro findings and confirm a role for
MMP-10 in the provision of a pro-tumor growth environ-
ment through an influence on angiogenesis and apoptosis.
Discussion
Our findings reveal that MMP-10 expression can induce
the expression of key molecules implicated in angio-
genesis, metastasis and apoptosis, major mechanisms
involved in the establishment and progression of ma-
lignant tumors. Though MMP-10 is well characterized
biochemically, compared to other MMPs, little is known
about MMP-10 in human cancers. Here, we are the first
to report the relative increased expression of MMP-10 in
human cervical cancer compared to benign tissue, and
that expression correlates with the invasive phenotype of
malignant cervical tumors. Given that we have recentlydemonstrated that MMP-10 expression at the RNA [20]
and protein level [21,22] is increased in urine samples ob-
tained from patients with bladder cancer, so there ap-
pears be a trend of association between malignancy and
MMP-10. Within this study, analysis of 188 tumor speci-
mens confirmed that MMP-10 protein expression was
increased in human bladder tumors, and, as in cer-
vical cancer study, a correlation between more aggres-
sive bladder cancers and MMP-10 expression was noted
(Additional file 2: Figure S1). Only one small study has
previously reported the expression of MMP-10 in human
bladder tumors. In that study, Seargent et al., demon-
strated that MMP-10 was predominantly present in the
epithelial component of tumor tissue, and that bladder
cancer had significantly greater levels of MMP-10 than be-
nign bladder specimens. However, the investigators could
not demonstrate a difference in MMP-10 expression be-
tween low stage and high stage disease, possibly due to the
small (n = 60) sample size [7]. Limited data are available
for MMP-10 expression in cervical tissue. However in a
small study, Vazquez-Ortiz et al. reported that overexpres-
sion of MMP-10 was observed to be consistently overex-
pressed in invasive cervical cancer biopsies associated by
cDNA array. Validation on an independent, large cohort
was not performed [25]. We must stress that HPV status
was not reported on the commercial TMA utilized in our
study. It would be interesting to investigate whether
MMP-10 expression is correlated with disease prognosis
in cervical and bladder cancers, as it has been in esopha-
geal carcinoma [26], current studies to address this are
underway.
MMP-10 (also known as stromelysin 2) is generally
limited to epithelial cells and its regulation is tightly
controlled [27]. For example, MMP-10 is not present in
intact normal skin, but is expressed during cutaneous in-
jury and repair where it is localized to the migrating ker-
atinocytes at the wound edge, alluding to its role as a
pro-invasion molecule [5]. In the HeLa cervical cancer
cell line, MMP-10 was not expressed in culture. How-
ever, when HeLa cells were grown in a 3D matrix (data
not shown), or as a xenograft tumor (Figure 6A), MMP-
10 expression was induced. This is similar to the report
by Mishra et al., who demonstrated that A549 human lung
cancer cells grown in an ex vivo 3D model expressed sig-
nificantly more MMP-10 than when grown as a mono-
layer culture [28]. Though benign (as defined by inability
to form xenograft tumors), the UROtsa cell line has been
transformed by SV40 [29], and thus has a non-functional
p53. This could account for the high level of MMP-10 ex-
pression, supporting a role for p53 in MMP-10 expression,
originally noted by Meyer et al. [24].
A considerable amount of information has accumu-
lated to suggest that the role of MMPs in cancer is far
more complicated than initially presumed. One such role
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proapoptotic or antiapoptotic effects depending on the
local cellular production and availability of proteolytic-
ally released and activated death-inducing and/or growth
and survival factors [30]. For example, proapoptotic ef-
fects can be due to degradation of ECM proteins that
serve as ligands for specific classes of integrins. In the
absence of the ligand, integrins can no longer trigger sig-
nals necessary for epithelial and endothelial survival thus
resulting in apoptosis. Alternatively, ECM degradation
can result in the release of IGF-1, which could directly
promote tumor cell resistance to proapototic signals. In
our study, HeLa cells (p53 wild-type) were found to be
more resistant to apoptosis when MMP-10 was expressed.
This resistance to apoptosis was associated with changes in
the expression of key molecules in both the intrinsic (e.g.,
reduction in Bax, Bak and cleaved caspase 8 and an in-
crease in Bcl-xl) and extrinsic apoptotic pathway (e.g., re-
duction in FasL and cleaved caspase 8).
An interesting co-expression relationship that we were
able to confirm was that between MMP-10 and PAI-1.
PAI-1 is an important endogenous inhibitor of
urokinase-type plasminogen activator. Specifically, PAI-1
normally functions as part of the plasminogen activation
(PA) system, which includes the serine protease uPA
(urokinase-type plasminogen activator), its receptor
uPA-R, tPA (tissue plasminogen activator) and inhibitors
PAI-1 and PAI-2 [31]. PAI-1 expression may be regu-
lated by many intrinsic factors (e.g., cytokines and
growth factors) and extrinsic factors (e.g., cellular stress)
[32]. Although the canonical function of PAI-1 has been
known as an inhibitor of uPA to maintain clot formation
[33] it is now regarded as a pleiotropic factor exerting
diverse cellular effects, many related to tumorigenesis;
cellular proliferation, migration, invasion, adhesion and
angiogenesis. The deregulation of PAI-1 has been corre-
lated to several tumor types (e.g., breast, colorectal, lung
and bladder) and has been associated as a poor prognos-
tic factor [34-40]. Previous studies have reported a posi-
tive correlation between MMP-10 and PAI-1 [41-43].
Similar, we report an increase of both MMP-10 and
PAI-1 in voided urine samples from subjects with blad-
der cancer [21,22]. Interesting, Wilkins et al. reported
that the addition of PAI-1 blocks collagen degradation
as well as the conversion of MMP-10 to its catalytically
active form. Thus there exist MMP-10/PAI-1/plasmin
dependent proteolytic axis that enhances ECM degrad-
ation and facilitates angiogenesis and invasion. Further
characterization of this axis may have far reaching impli-
cations for therapeutic targeting of human malignancies.
Conclusions
In a series of in vitro and in vivo experiments, MMP-10
activity was shown to be pivotal in the tumor growth ina mouse model of cancer, and the expression of this
MMP is associated with the upregulation of key mole-
cules related to angiogenesis, metastasis, and apoptosis,
creating a milieu favorable to the survival and expansion
of malignant lesions. Furthermore, demonstration of a
correlation between MMP-10 expression and invasive
cervical and bladder cancers supports a role for MMP-
10 in human tumor progression. These data suggest that
MMP-10 may have value as a novel biomarker and/or
provide a molecular target for therapeutic intervention.Additional files
Additional file 1: Immunohistochemcal evaluation of tissue
microarrays.
Additional file 2: Figure S1. MMP-10 expression pattern in human
bladder cancer. Representative images of normal urothelium (A) and of
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MMP-10 expression in the tumor epithelia (G). Scale bars, 100 μm. H,
quantification of MMP-10 expression levels in benign bladder tissue (n = 70)
vs. bladder tumor (n = 188). I, quantification of MMP-10 expression levels in
non-muscle invasive bladder cancer (NMIBC) vs. muscle invasive bladder
cancer (MIBC). Increased MMP-10 expression was noted in bladder tumors
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Additional file 3: Table S1. RT2 Profiler PCR Array for Angiogenesis
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